RxDoctor Payments Data

John Glendening, PA

Medical · Orange, CANPI 1851490486

Payments from drug & device makers

$4,218in general payments, 2019–2025

Across 232 payments — averaging $18.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$392
  • Myovant Sciences Inc.$355
  • E.r. Squibb & Sons, L.L.C.$348
  • Seagen Inc.$312
  • Exelixis Inc.$269
  • Bristol Myers Squibb$202
  • plus $2K from 40 others

What the payments were for

  • Food & beverage$4,07897%
  • Education$1413%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,218 in reported general payments places this provider in the 85th percentile of 2,087 medical providers in California.

See all medical providers in California

Medicare billing

Part B allowed, 2024
$25,963
Medicare patients
69
Services billed
313

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate88$1,444,998
XtandiEnzalutamide108$1,370,911
LorbrenaLorlatinib15$323,603
AlecensaAlectinib Hcl12$222,965
ErleadaApalutamide15$222,955
TabrectaCapmatinib Hydrochloride14$205,076
GilotrifAfatinib Dimaleate16$184,235
Abiraterone Acetate94$157,503
EliquisApixaban68$42,001
Dexamethasone34$572
Prochlorperazine Maleate26$436
Oxycodone Hcl29$424
Prednisone95$335
Ondansetron OdtOndansetron15$227
Metoprolol Succinate14$175

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso$392$1,444,99888 claims
Astellas Pharma US IncXtandi$35$1,370,911108 claims
PfizerLorbrena, Eliquis$12$365,60483 claims
Johnson & JohnsonErleada$134$222,95515 claims
NovartisTabrecta$149$205,07614 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$78$157,50394 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,087 medical providers in California.

Other medical in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →